Topiramate monotherapy as broad-spectrum antiepileptic drug

Objective: To explore seizure outcomes and tolerability of topiramate (TPM) in mono- or conversion to monotherapy in patients with recently diagnosed epilepsy (epilepsy duration ≤3 years). Methods: Prospective, open label, single arm, multicentre phase IV clinical trial (TOP-GER-5). Patients ≥18 years were followed for 28 weeks. Doses of TPM and concomitant antiepileptic drugs could be adjusted individually. Seizure frequency and adverse events were documented at each visit. Results: The ITT population consisted of 191 patients (56% male, mean age overall 39.7±15.9 years). 39% started topiramate as initial monot…